Market Overview

Seattle Genetics Rallies To Record High On Positive Results From Midstage Breast Cancer Study

Seattle Genetics Rallies To Record High On Positive Results From Midstage Breast Cancer Study

Shares of the large-cap biopharma Seattle Genetics, Inc. (NASDAQ: SGEN) were advancing strongly Monday following a clinical trial readout from the company.

Primary, Secondary Endpoints Met

A pivotal Phase 2 trial dubbed HER2CLIMB that evaluated tucatinib in combination with Roche Holdings AG Basel ADR (OTC: RHHBY)'s Herceptin and chemotherapy medication capecitabine versus Herceptin and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer met the primary as well as both key secondary endpoints, Seattle Genetics said in a press release. 

The comparator study showed that the trial met the primary endpoint of progression-free survival, with tucatinib found superior to Herceptin and capecitabine alone and achieving a 46% reduction in the risk of disease progression or death.

Interim analysis also showed that the trial met two key secondary points: an overall improvement in overall survival, with a 34% reduction in the risk of death, and superior progression-free survival in breast cancer patients with brain metastases at baseline, Seattle Genetics said.

The company acquired the asset through its 2018 acquisition of Cascadian Therapeutics for $614 million.

The triplet therapy was generally well-tolerated, with a manageable safety profile, the company said. Significant Unmet Need

Seattle Genetics said there is a significant unmet need following treatment with Herceptin, pertuzumab and T-DM1 in patients with metastatic HER-2 positive breast cancer.

"The addition of tucatinib to the commonly used doublet of trastuzumab and capecitabine represents a potential significant clinical advance for patients with metastatic HER2-positive breast cancer, importantly, including those with brain metastases," Roger Dansey, chief medical officer at Seattle Genetics, said in a statement. 

What's Next 

Based on the findings, Seattle Genetics plans to unblind the trial and offer tucatinib in patients on the control arm.

It is also intends to submit an NDA to the FDA in the first quarter of 2020.

Additional results from the study will be presented Dec. 11 at the 2019 San Antonio Breast Cancer Symposium, the company said. 

Seattle Genetics shares were rallying by 14.73% to $100.27 off the open Monday. 

Related Links:

Biotech Stock On The Radar: Assessing Mirati's Oncology Franchise With An Eye On Multiple Readouts

The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict

Posted-In: Biotech News Trading Ideas Best of Benzinga


Related Articles (SGEN + RHHBY)

View Comments and Join the Discussion!

Monday's Market Minute: Another Big Week Ahead…

12 Cheapest Cash Flow Stocks In The S&P 500